Antiproliferative Benzoindazolequinones As Potential Cyclooxygenase-2 Inhibitors

Overview

Journal Molecules

Publisher MDPI

Specialty Biology

Date 2019 Jun 21

PMID 31216654

Citations 3

Authors

Aurora Molinari

Alfonso Oliva

Marlene Arismendi-Macuer

Leda Guzman

Waldo Acevedo

Daniel Aguayo

Raul Vinet

Arturo San Feliciano

Affiliations

Soon will be listed here.

Abstract

Quinones and nitrogen heterocyclic moieties have been recognized as important pharmacophores in the development of antitumor agents. This study aimed to establish whether there was any correlation between the in silico predicted parameters and the in vitro antiproliferative activity of a family of benzoindazolequinones (BIZQs), and to evaluate overexpressed proteins in human cancer cells as potential biomolecular targets of these compounds. For this purpose, this study was carried out using KATO-III and MCF-7 cell lines as in vitro models. Docking results showed that these BIZQs present better binding energies (ΔG) values for cyclooxygenase-2 (COX-2) than for other cancer-related proteins. The predicted ∆G values of these BIZQs, classified in three series, positively correlated with IC measured in both cell lines (KATO-III: 0.72, 0.41, and 0.90; MCF-7: 0.79, 0.55, and 0.87 for Series I, II, and III, respectively). The results also indicated that compounds , , , and are the most prominent BIZQs, because they showed better IC and ∆G values than the other derivatives. In silico drug absorption, distribution, metabolism, and excretion (ADME) properties of the three series were also analyzed and showed that several BIZQs could be selected as potential candidates for cancer pre-clinical assays.

Citing Articles

Synthesis, Anticancer Activity, and Docking Studies of Novel Hydroquinone-Chalcone-Pyrazoline Hybrid Derivatives.

Maldonado J, Oliva A, Guzman L, Molinari A, Acevedo W Int J Mol Sci. 2024; 25(13).

PMID: 39000394 PMC: 11242894. DOI: 10.3390/ijms25137281.

2-Acetyl-5,8-dihydro-6-(4-methyl-3-pentenyl)-1,4-naphthohydroquinone-Derived Chalcones as Potential Anticancer Agents.

Maldonado J, Oliva A, Molinari A, Acevedo W Molecules. 2023; 28(20).

PMID: 37894650 PMC: 10609043. DOI: 10.3390/molecules28207172.

In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones.

Sanachai K, Mahalapbutr P, Tabtimmai L, Seetaha S, Kaekratoke N, Chamni S Molecules. 2023; 28(2).

PMID: 36677654 PMC: 9866339. DOI: 10.3390/molecules28020597.

References

Berman H, Westbrook J, Feng Z, Gilliland G, Bhat T, Weissig H . The Protein Data Bank. Nucleic Acids Res. 1999; 28(1):235-42. PMC: 102472. DOI: 10.1093/nar/28.1.235. View

Curtis Hewitt S, Couse J, Korach K . Estrogen receptor transcription and transactivation: Estrogen receptor knockout mice: what their phenotypes reveal about mechanisms of estrogen action. Breast Cancer Res. 2001; 2(5):345-52. PMC: 138656. DOI: 10.1186/bcr79. View

Lipinski C, Lombardo F, Dominy B, Feeney P . Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv Drug Deliv Rev. 2001; 46(1-3):3-26. DOI: 10.1016/s0169-409x(00)00129-0. View

Jorgensen W, Duffy E . Prediction of drug solubility from structure. Adv Drug Deliv Rev. 2002; 54(3):355-66. DOI: 10.1016/s0169-409x(02)00008-x. View

Singh B, Berry J, Shoher A, Ramakrishnan V, Lucci A . COX-2 overexpression increases motility and invasion of breast cancer cells. Int J Oncol. 2005; 26(5):1393-9. View

He M, Rosen J, Mangiameli D, Libutti S . Cancer development and progression. Adv Exp Med Biol. 2007; 593:117-33. DOI: 10.1007/978-0-387-39978-2_12. View

Svrcek M, El-Bchiri J, Chalastanis A, Capel E, Dumont S, Buhard O . Specific clinical and biological features characterize inflammatory bowel disease associated colorectal cancers showing microsatellite instability. J Clin Oncol. 2007; 25(27):4231-8. DOI: 10.1200/JCO.2007.10.9744. View

Izzo J, Ajani J . Thinking in and out of the box when it comes to gastric cancer and cyclooxygenase-2. J Clin Oncol. 2007; 25(31):4865-7. DOI: 10.1200/JCO.2007.13.1060. View

Trott O, Olson A . AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading. J Comput Chem. 2009; 31(2):455-61. PMC: 3041641. DOI: 10.1002/jcc.21334. View

10.

Sobolewski C, Cerella C, Dicato M, Ghibelli L, Diederich M . The role of cyclooxygenase-2 in cell proliferation and cell death in human malignancies. Int J Cell Biol. 2010; 2010:215158. PMC: 2841246. DOI: 10.1155/2010/215158. View

11.

Xu C, Guo J, Jiang Z, Xie S, Shen J, Shen J . Prognostic role of estrogen receptor alpha and estrogen receptor beta in gastric cancer. Ann Surg Oncol. 2010; 17(9):2503-9. DOI: 10.1245/s10434-010-1031-2. View

12.

Kato M, Asaka M . Recent knowledge of the relationship between Helicobacter pylori and gastric cancer and recent progress of gastroendoscopic diagnosis and treatment for gastric cancer. Jpn J Clin Oncol. 2010; 40(9):828-37. DOI: 10.1093/jjco/hyq119. View

13.

Shibuya M . Vascular Endothelial Growth Factor (VEGF) and Its Receptor (VEGFR) Signaling in Angiogenesis: A Crucial Target for Anti- and Pro-Angiogenic Therapies. Genes Cancer. 2012; 2(12):1097-105. PMC: 3411125. DOI: 10.1177/1947601911423031. View

14.

Kieran M, Kalluri R, Cho Y . The VEGF pathway in cancer and disease: responses, resistance, and the path forward. Cold Spring Harb Perspect Med. 2012; 2(12):a006593. PMC: 3543071. DOI: 10.1101/cshperspect.a006593. View

15.

Tacar O, Sriamornsak P, Dass C . Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol. 2013; 65(2):157-70. DOI: 10.1111/j.2042-7158.2012.01567.x. View

16.

Sepulveda A . Helicobacter, Inflammation, and Gastric Cancer. Curr Pathobiol Rep. 2013; 1(1):9-18. PMC: 3655720. DOI: 10.1007/s40139-013-0009-8. View

17.

Florea A, Busselberg D . Cisplatin as an anti-tumor drug: cellular mechanisms of activity, drug resistance and induced side effects. Cancers (Basel). 2013; 3(1):1351-71. PMC: 3756417. DOI: 10.3390/cancers3011351. View

18.

Zarghi A, Arfaei S . Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships. Iran J Pharm Res. 2013; 10(4):655-83. PMC: 3813081. View

19.

Xu L, Stevens J, Hilton M, Seaman S, Conrads T, Veenstra T . COX-2 inhibition potentiates antiangiogenic cancer therapy and prevents metastasis in preclinical models. Sci Transl Med. 2014; 6(242):242ra84. PMC: 6309995. DOI: 10.1126/scitranslmed.3008455. View

20.

Abdel-Rahman O . Targeting vascular endothelial growth factor (VEGF) pathway in gastric cancer: preclinical and clinical aspects. Crit Rev Oncol Hematol. 2014; 93(1):18-27. DOI: 10.1016/j.critrevonc.2014.05.012. View